NRTI — guanosine analog, phosphorylated to carbovir-TP, a chain-terminator for HIV reverse transcriptase. HLA-B*5701 carriers (~5% of populations of European descent) develop life-threatening hypersensitivity → mandatory pre-treatment genotyping.
Half-Life & Elimination Curve (PO: 1.5h)
Plasma (PO)t½ Decay (1.5h)
0×t½0h100%(4.91 mg/L)
1×t½1.5h50%(2.46 mg/L)
2×t½3h25%(1.23 mg/L)
3×t½4.5h12.5%(0.614 mg/L)
4×t½6h6.3%(0.307 mg/L)
5×t½7.5h3.1%(0.154 mg/L)
Elimination t½1.5h (PO)
Rate Constant (ke)0.462 h⁻¹
Time to Peak (Tmax)1.13h
Est. Peak (Cmax)4.91 mg/L
Clearance (CL)27.7 L/h
97% Washout (5×t½)7.5h
Dosing Guidelines
Oral (PO): Typical 600 mg (Range: 300–600 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 83% · Volume of Distribution (Vd): 60 L · Absorption (ka): 1.5 h⁻¹ (t½ka ≈ 28m) [PMID 18479171]